At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 35 enrolled
Drug / intervention
Erdafitinib +2 moredrug
Likely dose
Erdafitinib 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
In Brief
A Phase 1 clinical trial evaluating Erdafitinib, Palbociclib, and 1 other intervention for Metastatic Breast Cancer. Completed, enrolled 35 participants across 6 sites.
Detailed Summary
This is an open-label, multi-institution, phase Ib trial that evaluates the safety and tolerability and preliminary anti-tumor activity of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionApr 2021
Study CompletionMar 2024
TodayJul 2026
First PostedAug 3, 2017
Enrollment StartAug 18, 2017
Primary CompletionApr 30, 2021
Study CompletionMar 20, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.9 years ago
Interventions
Erdafitinibdrug
4mg - 8mg
Palbociclibdrug
125 mg
Fulvestrantdrug
500 mg